<DOC>
	<DOCNO>NCT02578238</DOCNO>
	<brief_summary>This study non-interventional , observational study Humira® treatment pediatric CD per New Drug Re-examination Guideline Korea . This study conduct institution provide write agreement AbbVie Korea , use Humira® pediatric CD follow normal medical practice setting . Pediatric patient prescribe Humira® per physician 's medical judgment accordance approve Summary Product Characteristics ( SmPC ) enrol study . As post marketing surveillance , AbbVie NOT involved product supply since drug use accord approved marketing label prescribe physician usual customary practice physician prescription .</brief_summary>
	<brief_title>Post-Marketing Surveillance Humira Korean Pediatric Crohn 's Disease ( CD ) Patients Under `` New-Drug Re-examination ''</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Pediatric patient Crohn 's Disease prescribe Humira accordance Korean label Humira authorization ( label ) Patients give write authorization use personal health data purpose study . Any contraindication Humira list approved product market authorization ( label ) Patients participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Korea</keyword>
	<keyword>Humira</keyword>
	<keyword>Pediatric Crohn 's Disease</keyword>
</DOC>